Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Oct 27;8(11):677.
doi: 10.3390/nu8110677.

Administration of a Multi-Strain Probiotic Product to Women in the Perinatal Period Differentially Affects the Breast Milk Cytokine Profile and May Have Beneficial Effects on Neonatal Gastrointestinal Functional Symptoms. A Randomized Clinical Trial

Maria Elisabetta Baldassarre  1 , Antonio Di Mauro  2 , Paola Mastromarino  3 , Margherita Fanelli  4 , Domenico Martinelli  5 , Flavia Urbano  6 , Daniela Capobianco  7 , Nicola Laforgia  8
Affiliations
Randomized Controlled Trial

Administration of a Multi-Strain Probiotic Product to Women in the Perinatal Period Differentially Affects the Breast Milk Cytokine Profile and May Have Beneficial Effects on Neonatal Gastrointestinal Functional Symptoms. A Randomized Clinical Trial

Maria Elisabetta Baldassarre et al. Nutrients. .

Abstract

Background: Probiotic supplementation to women during pregnancy and lactation can modulate breast milk composition, with immune benefits being transferred to their infants.

Aim: The aim of the study was to evaluate the effect of high-dose probiotic supplementation to women during late pregnancy and lactation on cytokine profile and secretory IgA (sIgA) in breast milk and thus to study if differences in breast milk composition can affect lactoferrin and sIgA levels in stool samples of newborns. The safety of maternal probiotic administration on neonatal growth pattern and gastrointestinal symptoms were also evaluated.

Methods: In a double-blind, placebo-controlled, randomized trial, 66 women took either the probiotic (n = 33) or a placebo (n = 33) daily. Levels of interleukins (IL-6, IL-10 and IL-1β), transforming growth factor-β1 (TGF-β1), and sIgA in breast milk; and the level of sIgA and lactoferrin in newborn stool samples were analyzed at birth and then again at one month of life. Antropometrical evaluation and analysis of gastrointestinal events in newborns was also performed.

Results: Probiotic maternal consumption had a significant impact on IL6 mean values in colostrum and on IL10 and TGF-β1 mean values in mature breast milk. Fecal sIgA mean values were higher in newborns whose mothers took the probiotic product than in the control group. Probiotic maternal supplementation seems to decrease incidence of infantile colic and regurgitation in infants.

Conclusion: High-dose multi-strain probiotic administration to women during pregnancy influences breast milk cytokines pattern and sIgA production in newborns, and seems to improve gastrointestinal functional symptoms in infants.

Keywords: functional GI diseases; immunology; pediatric gastroenterology; probiotics/prebiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Breast milk cytokine patterns in treatment (T) and control (C) newborns at observational times T0 and T30. (A) (Interleukin-1β mean values); (B) (Inteleukin-10 mean values); (C) (Interleukin-6 mean values); (D) (Transforming Growth Factor mean values).
Figure 3
Figure 3
Secretory IgA (sIgA) in breast milk and stools, in treatment (T) and control (C) groups at observational times T0 and T30. (A) (Secretory IgA (sIgA) mean values in breast milk); (B) (Secretory IgA (sIgA) mean values in stools).
Figure 4
Figure 4
Fecal lactoferrin in treatment (T) and control (C) groups at observational times T0 and T30.
Figure 5
Figure 5
Growth pattern in treatment (T) and control (C) groups.
Figure 6
Figure 6
Functional gastrointestinal disorders (FGIDs) in treatment (T) and control (C) groups.
See this image and copyright information in PMC

References

    1. Rautava S., Luoto R., Salminen S., Isolauri E. Microbial contact during pregnancy, intestinal colonization and human disease. Nat. Rev. Gastroenterol. Hepatol. 2012;9:565–576. doi: 10.1038/nrgastro.2012.144. - DOI - PubMed
    1. Crosby M.S., Blattner C.M., Goedken M., Murase J.E. Update: Do probiotics prevent or treat pediatric atopic dermatitis? Pediatr. Allergy Immunol. 2016;27:425–428. - PubMed
    1. Vitali B., Cruciani F., Baldassarre M.E., Capursi T., Spisni E., Valerii M.C., Candela M., Turroni S., Brigidi P. Dietary supplementation with probiotics during late pregnancy: Outcome on vaginal microbiota and cytokine secretion. BMC Microbiol. 2012;12:236. doi: 10.1186/1471-2180-12-236. - DOI - PMC - PubMed
    1. Di Mauro A., Neu J., Riezzo G., Raimondi F., Martinelli D., Francavilla R., Indrio F. Gastrointestinal function development and microbiota. Ital. J. Pediatr. 2013;39:15. doi: 10.1186/1824-7288-39-15. - DOI - PMC - PubMed
    1. Mastromarino P., Capobianco D., Miccheli A., Praticò G., Campagna G., Laforgia N., Capursi T., Baldassarre M.E. Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery. Pharmacol. Res. 2015;95–96:63–70. - PubMed

Publication types

MeSH terms